Glucagon

Generic Name: Glucagon

Brand Names: Baqsimi, Glucagen, Gvoke, Ogluo

Drug Type: Biotech

CAS Number: 16941-32-5

Unique Ingredient Identifier: 76LA80IG2G

Background: Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.

Glucagon was granted FDA approval on 14 November 1960.

Indication: Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.

Associated Conditions: Severe Hypoglycemia

Clinical Trials

The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance.

Not Applicable

Not yet recruiting

Conditions: Kidney Diseases

Interventions: Drug: Glucagon
Drug: Glucagon+Exendin9-39
Drug: Sodium chloride

First Posted Date: 2025-03-12

Last Posted Date: 2025-03-12

Lead Sponsor: Bispebjerg Hospital

Target Recruit Count: 10

Registration Number: NCT06872060

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Phase 1

Recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Dasiglucagon
Drug: Glucagon

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 38

Registration Number: NCT06588504

Locations: 🇯🇵
Hakata Clinic, Fukuoka, Japan

Human Models of Selective Insulin Resistance: Pancreatic Clamp

Phase 1

Not yet recruiting

Conditions: Insulin Resistance
Hyperinsulinemia
Metabolic Dysfunction Associated Steatotic Liver Disease
Non-Alcoholic Fatty Liver Disease
Prediabetic State
Obesity

Interventions: Drug: Insulin human
Drug: Octreotide Acetate
Drug: Glucagon
Drug: Growth Hormone, Human
Drug: 20% D-glucose (aq)
Diagnostic Test: [6,6-2H2] D-glucose
Diagnostic Test: [1-13C1] sodium acetate
Dietary Supplement: Nestle BOOST Plus
Dietary Supplement: KIND Bar
Device: Harvard Apparatus PHD ULTRA CP syringe pump
Device: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer

First Posted Date: 2024-08-16

Last Posted Date: 2025-01-08

Lead Sponsor: Columbia University

Target Recruit Count: 36

Registration Number: NCT06558422

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

Recruiting

Conditions: Crohn Disease

Interventions: Drug: Radiotracer Injection
Drug: Contrast Media, Magnetic Resonance
Diagnostic Test: Blood Draw
Drug: Glucagon
Diagnostic Test: Imaging
Drug: Oral contrast media application

First Posted Date: 2024-02-09

Last Posted Date: 2024-02-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 25

Registration Number: NCT06252493

Locations: 🇺🇸
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States

Dexamethasone/Pancreatic Clamp P&F

Phase 1

Withdrawn

Conditions: Insulin Resistance
Non-Alcoholic Fatty Liver Disease
Prediabetic State
Overweight and Obesity

Interventions: Drug: Insulin human
Drug: Octreotide Acetate
Drug: Glucagon
Drug: Human Growth Hormone
Drug: Dexamethasone Oral
Other: [6,6-2H2] D-glucose
Drug: 20% D-glucose (aq)
Dietary Supplement: BOOST Plus
Device: Harvard Apparatus PHD ULTRA CP syringe pump
Device: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer
Other: Normal saline
Other: Human albumin

First Posted Date: 2023-11-13

Last Posted Date: 2024-07-10

Lead Sponsor: Columbia University

Registration Number: NCT06126354

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Glucagon Enhanced Insulin Absorption in Diabetes Mellitus Type 1

Phase 2

Recruiting

Conditions: Type 1 Diabetes

Interventions: Drug: Glucagon

First Posted Date: 2023-07-25

Last Posted Date: 2023-07-25

Lead Sponsor: St. Olavs Hospital

Target Recruit Count: 30

Registration Number: NCT05960565

Locations: 🇳🇴
Department of Endocrinology, St. Olavs Hospital, Trondheim, Norway

Pancreatic Clamp in NAFLD

Phase 1

Suspended

Conditions: Obesity
Prediabetic State
Insulin Resistance
Hyperinsulinemia
Non-Alcoholic Fatty Liver Disease

Interventions: Drug: Insulin human
Drug: Octreotide Acetate
Drug: Glucagon
Drug: Growth Hormone, Human
Other: [6,6-2H2] D-glucose
Drug: 20% D-glucose (aq)
Dietary Supplement: BOOST Plus
Dietary Supplement: CORE Bar
Device: Harvard Apparatus PHD ULTRA CP syringe pump
Device: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer

First Posted Date: 2023-02-13

Last Posted Date: 2025-04-03

Lead Sponsor: Columbia University

Target Recruit Count: 42

Registration Number: NCT05724134

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

The Effects of Glucagon on Hepatic Metabolism

Phase 1

Recruiting

Conditions: Type2diabetes
Obesity
NAFLD

Interventions: Drug: Glucagon response study

First Posted Date: 2022-08-15

Last Posted Date: 2024-05-29

Lead Sponsor: Adrian Vella

Target Recruit Count: 60

Registration Number: NCT05500586

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Second-line Therapies for Patients with Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Active, not recruiting

Conditions: Type 2 Diabetes
Cardiac Disease

Interventions: Drug: Glucagon like peptide 1 receptor agonist
Drug: Sodium-glucose cotransporter 2 inhibitor
Drug: Dipeptidyl Peptidase 4 Inhibitor
Drug: Sulfonylurea

First Posted Date: 2022-01-28

Last Posted Date: 2024-10-16

Lead Sponsor: Mayo Clinic

Target Recruit Count: 500000

Registration Number: NCT05214573

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States

Metabolic Adaptation to High-frequent Hypoglycaemia in Type 1 Diabetes

Not Applicable

Active, not recruiting

Conditions: Type1diabetes

Interventions: Drug: insulin human
Drug: Epinephrin
Procedure: Muscle biopsy
Procedure: Adipose tissue biopsy
Drug: Glucagon
Device: IPRO 2 Medtronic Minimed
Procedure: 7 Tesla (7T) Magnetic Resonance Imaging
Procedure: Indirect Calorimetry using Jaeger Oxycon Champion
Procedure: Core temperature and thermography using Thermovision SC645
Device: Freestyle Libre 2

First Posted Date: 2021-10-27

Last Posted Date: 2023-05-03

Lead Sponsor: Nordsjaellands Hospital

Target Recruit Count: 60

Registration Number: NCT05095259

Locations: 🇩🇰
Nordsjaellands Hospital, Hillerød, Denmark
🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy